Entera Bio(ENTX)

Israel - JerusalemBiotechnology2 H-1B visas (FY2023)

Focus: Entera Bio is an Israeli-headquartered public biotech focused on oral biologics delivery, currently monetizing through generic ANDA products while advancing Phase 1-2 programs in bone and mineral metabolism.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

2 recent layoff filings (12 mo) — 110 affected

2/17/2026 — 1209 W 98th St. Chicago, IL 60643, IL · 44 affected · Closure
2/17/2026 — 1620 W Chase Chicago, IL 60626, IL · 66 affected · Closure

Source: state DOL filings via Big Local News

About Entera Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Entera Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$181K

Key Products

VINCRISTINE SULFATE

Oncology (indicated use not specified)

$7K Part D

Pre-Launch

Despite representing 76% of company revenue concentration, this ANDA product generates minimal Part D spending, indicating commercial traction failure or market timing issues.

Help build intelligence for Entera Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside and exit clarity in a speculative pipeline (6 active trials in early phases)
Novel oral biologics platform targeting underserved indications (osteoporosis, hypoparathyroidism) with proprietary delivery technology
International (Israel-based) biotech with H1B sponsorship track record (2 approvals, 0 denials in 2023)

Watch Out For

Extreme financial distress: $181K FY2025 revenue against $4M R&D spend and $9.5M net losses; only $9M cash remaining creates 12-18 month runway risk
No Phase 3 programs and early-stage pipeline (3 Phase 1, 3 Phase 2) means 5+ years to potential revenue; generic product portfolio offers minimal competitive moat

Generated by Claude from Entera Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

AMPHOTERICIN B

Cryptococcal meningitis (HIV), visceral leishmaniasis

$2K Part D

Post-LOE

Post-LOE generic competing in crowded antifungal space with minimal measurable Part D penetration.

BLEOMYCIN SULFATE

Lymphoma

Post-LOE

Historic oncology agent now off-patent; low commercial priority for company.

THIOTEPA

Alkylating agent for oncology

Post-LOE